Skip to Main Content

As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of its KRAS-targeting lung cancer drug later this year, final results from a clinical trial reported Thursday could both help and hinder the biotech’s efforts to stand apart from a rival Amgen treatment approved one year ago.

In its own clinical trial, the Mirati drug, called adagrasib, shrank tumors in 43% of patients with advanced lung cancer — a result that tops the 37% response rate from a study reported by Amgen for its drug, called Lumakras.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment